Evaluation of the Ocular Tolerance of Three Tacrolimus Topical Pharmaceutical Preparations by Bovine Corneal Opacity and Permeability Test

ABSTRACT Purpose: Tacrolimus ocular preparations are commonly employed in autoimmune or inflammatory ocular disorders. However, currently there are not yet approved ocular formulations. Tacrolimus ocular side effects have been reported in clinical use, so the evaluation of different pharmaceutical preparations is mandatory. In this study, the local corneal tolerance and safety profile of three common tacrolimus 0.03% pharmaceutical preparations were evaluated. Material and methods: Corneal irritation and permeability of tacrolimus preparations were evaluated with the bovine corneal opacity and permeability (BCOP) test. Complementary corneal hematoxylin/eosin and immunohistochemistry staining for tight junctions and adherent junctions E-cadherin, VE-cadherin and zonula occludens-1 were examined and scored to evaluate and to confirm corneal disruption and irritation scores obtained with the BCOP method. Results: Commercial brand ointment (Protopic®), topical compounded eye ointment (pharmacy elaboration) and tacrolimus suspension eye drops (elaborated from parenteral prograf®) were tested as potential ocular preparations to be used in clinics. Tacrolimus preparations hereby studied do not alter the opacity and permeability of the bovine cornea by more than three units, measured by the In Vitro Irritancy Score, neither affected the immunohistochemical parameters, composite score or transepithelial electrical resistance. Conclusions: Tacrolimus preparations studied can be safely applied as a topical ocular treatment.

[1]  E. Takamura,et al.  Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement , 2014, British Journal of Ophthalmology.

[2]  J. Pluta,et al.  Ophthalmic Drug Dosage Forms: Characterisation and Research Methods , 2014, TheScientificWorldJournal.

[3]  A. Al-Amri.  Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis. , 2014, American journal of ophthalmology.

[4]  D. Marinho,et al.  Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study , 2013, British Journal of Ophthalmology.

[5]  T. Gray,et al.  Human corneal anatomy redefined: a novel pre-Descemet's layer (Dua's layer). , 2013, Ophthalmology.

[6]  Zuguo Liu,et al.  Serine protease inhibitor A3K protects rabbit corneal endothelium from barrier function disruption induced by TNF-α. , 2013, Investigative ophthalmology & visual science.

[7]  Frank A Barile,et al.  Alternative methods for ocular toxicology testing: validation, applications and troubleshooting , 2013, Expert opinion on drug metabolism & toxicology.

[8]  H. Ziv,et al.  Topical tacrolimus for the management of acute allergic conjunctivitis in a mouse model , 2013, Graefe's Archive for Clinical and Experimental Ophthalmology.

[9]  J. Cortijo,et al.  Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke , 2013, Thorax.

[10]  F. Paulsen,et al.  Structural and Functional Alteration of Corneal Epithelial Barrier Under Inflammatory Conditions , 2012, Current eye research.

[11]  P. Vichyanond,et al.  A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. , 2012, Asian Pacific journal of allergy and immunology.

[12]  R. Alany,et al.  Conjunctival and corneal tolerability assessment of ocular naltrexone niosomes and their ingredients on the hen's egg chorioallantoic membrane and excised bovine cornea models. , 2012, International journal of pharmaceutics.

[13]  Nuo Dong,et al.  Localization and Expression of Zonula Occludins-1 in the Rabbit Corneal Epithelium following Exposure to Benzalkonium Chloride , 2012, PloS one.

[14]  M. Stern,et al.  Topical Calcineurin Inhibitors in the Treatment of Steroid-Dependent Atopic Keratoconjunctivitis , 2012, Cornea.

[15]  J. Forrester,et al.  A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. , 2012, Ophthalmology.

[16]  Jin Pu,et al.  E-cadherin plays an essential role in collective directional migration of large epithelial sheets , 2012, Cellular and Molecular Life Sciences.

[17]  E. Takamura,et al.  Blood level of tacrolimus in patients with severe allergic conjunctivitis treated by 0.1% tacrolimus ophthalmic suspension. , 2012, Allergology international : official journal of the Japanese Society of Allergology.

[18]  Hans Raabe,et al.  The Bovine Corneal Opacity and Permeability Test in Routine Ocular Irritation Testing and its Improvement within the Limits of OECD Test Guideline 437 , 2011, Alternatives to laboratory animals : ATLA.

[19]  J. Avalos,et al.  Survey of ocular irritation predictive capacity using Chorioallantoic Membrane Vascular Assay (CAMVA) and Bovine Corneal Opacity and Permeability (BCOP) test historical data for 319 personal care products over fourteen years. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[20]  Jae-Hak Park,et al.  A new 3D reconstituted human corneal epithelium model as an alternative method for the eye irritation test. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[21]  K. Ward,et al.  Effect of a novel multipurpose contact lens solution on human corneal epithelial barrier function. , 2010, Contact lens & anterior eye : the journal of the British Contact Lens Association.

[22]  A. Young,et al.  Topical tacrolimus 0.03% monotherapy for vernal keratoconjunctivitis—case series , 2010, British Journal of Ophthalmology.

[23]  A. Young,et al.  Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD , 2010, Bone Marrow Transplantation.

[24]  Frank A Barile,et al.  Validating and troubleshooting ocular in vitro toxicology tests. , 2010, Journal of pharmacological and toxicological methods.

[25]  M. Thiel,et al.  [Safety of treatment with tacrolimus ointment for anterior segment inflammatory diseases]. , 2009, Klinische Monatsblatter fur Augenheilkunde.

[26]  J. C. Barrera,et al.  Pomada oftálmica de tacrolimus para el tratamiento de úlceras corneales inmunológicas , 2009 .

[27]  J. Cabeza Barrera,et al.  [Ophthalmic tacrolimus cream for the treatment of immunological corneal ulcers]. , 2009, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.

[28]  A. Kheirkhah,et al.  Characterization and comparison of intercellular adherent junctions expressed by human corneal endothelial cells in vivo and in vitro. , 2008, Investigative ophthalmology & visual science.

[29]  K. Fukuda,et al.  Delayed disruption of barrier function in cultured human corneal epithelial cells induced by tumor necrosis factor-alpha in a manner dependent on NF-kappaB. , 2008, Investigative ophthalmology & visual science.

[30]  G. Kymionis,et al.  Tacrolimus Ointment 0.03% in the Eye for Treatment of Giant Papillary Conjunctivitis , 2008, Cornea.

[31]  Y. Gerber,et al.  Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open-Label Pilot Study , 2008, Current eye research.

[32]  A. Dick,et al.  Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. , 2007, Ophthalmology.

[33]  Hannele M Virtanen,et al.  Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. , 2006, Acta ophthalmologica Scandinavica.

[34]  M. Hussein.  Analysis of Bcl-2 protein expression in choroidal melanomas , 2005, Journal of Clinical Pathology.

[35]  H. Sasaki,et al.  Synergistic effect of EDTA and boric acid on corneal penetration of CS-088. , 2005, International journal of pharmaceutics.

[36]  T. Reinhard,et al.  Topical FK506 as immunoprophylaxis after allogeneic penetrating normal‐risk keratoplasty: a randomized clinical pilot study , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[37]  K. Tsubota,et al.  Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction. , 2002, Ophthalmology.

[38]  E. Letko,et al.  Treatment of ocular cicatricial pemphigoid with tacrolimus (FK 506) , 2001, Graefe's Archive for Clinical and Experimental Ophthalmology.

[39]  H Raabe,et al.  Prediction of ocular irritancy of prototype shampoo formulations by the isolated rabbit eye (IRE) test and bovine corneal opacity and permeability (BCOP) assay. , 2001, Toxicology in vitro : an international journal published in association with BIBRA.

[40]  V. Armstrong,et al.  New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. , 2001, Clinical biochemistry.

[41]  R. Berkowitz,et al.  Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. , 2000, The American journal of pathology.

[42]  A. Ringvold,et al.  Toxicological evaluation of cyclosporine eyedrops. , 1999, Acta ophthalmologica Scandinavica.

[43]  J. Zieske,et al.  ZO1 in corneal epithelium: association to the zonula occludens and adherens junctions. , 1997, Experimental eye research.

[44]  M. Liebert.  2: Final Report on the Safety Assessment of Propylene Carbonate , 1987 .